CN1420176A - 高效表达重组水蛭素及其生产方法 - Google Patents
高效表达重组水蛭素及其生产方法 Download PDFInfo
- Publication number
- CN1420176A CN1420176A CN 01141415 CN01141415A CN1420176A CN 1420176 A CN1420176 A CN 1420176A CN 01141415 CN01141415 CN 01141415 CN 01141415 A CN01141415 A CN 01141415A CN 1420176 A CN1420176 A CN 1420176A
- Authority
- CN
- China
- Prior art keywords
- dna
- sequence
- hirudin
- novel
- variation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 title claims description 9
- WQPDUTSPKFMPDP-OUMQNGNKSA-N hirudin Chemical compound C([C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC(OS(O)(=O)=O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H]1NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H]2CSSC[C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)N[C@H](C(NCC(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N2)=O)CSSC1)C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=2C=CC(O)=CC=2)NC(=O)[C@@H](NC(=O)[C@@H](N)C(C)C)C(C)C)[C@@H](C)O)CSSC1)C(C)C)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 WQPDUTSPKFMPDP-OUMQNGNKSA-N 0.000 title abstract description 7
- 229940006607 hirudin Drugs 0.000 claims abstract description 36
- 239000013604 expression vector Substances 0.000 claims abstract description 8
- 210000004027 cell Anatomy 0.000 claims abstract 16
- 150000001413 amino acids Chemical group 0.000 claims description 21
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 17
- 239000002773 nucleotide Substances 0.000 claims description 13
- 125000003729 nucleotide group Chemical group 0.000 claims description 13
- 239000000047 product Substances 0.000 claims description 12
- 229930183912 Cytidylic acid Natural products 0.000 claims description 10
- IERHLVCPSMICTF-XVFCMESISA-N cytidine 5'-monophosphate Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(O)=O)O1 IERHLVCPSMICTF-XVFCMESISA-N 0.000 claims description 10
- IERHLVCPSMICTF-UHFFFAOYSA-N cytidine monophosphate Natural products O=C1N=C(N)C=CN1C1C(O)C(O)C(COP(O)(O)=O)O1 IERHLVCPSMICTF-UHFFFAOYSA-N 0.000 claims description 10
- 108020004414 DNA Proteins 0.000 claims description 9
- RQFCJASXJCIDSX-UUOKFMHZSA-N guanosine 5'-monophosphate Chemical compound C1=2NC(N)=NC(=O)C=2N=CN1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O RQFCJASXJCIDSX-UUOKFMHZSA-N 0.000 claims description 9
- 235000013928 guanylic acid Nutrition 0.000 claims description 9
- 239000004226 guanylic acid Substances 0.000 claims description 9
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 claims description 6
- 241000545744 Hirudinea Species 0.000 claims description 6
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 claims description 6
- 229960001230 asparagine Drugs 0.000 claims description 6
- 235000009582 asparagine Nutrition 0.000 claims description 6
- 239000013612 plasmid Substances 0.000 claims description 6
- 238000000746 purification Methods 0.000 claims description 5
- 238000003259 recombinant expression Methods 0.000 claims description 5
- 238000000926 separation method Methods 0.000 claims description 5
- 101710194907 Hirudin-2 Proteins 0.000 claims description 4
- XUYPXLNMDZIRQH-LURJTMIESA-N N-acetyl-L-methionine Chemical compound CSCC[C@@H](C(O)=O)NC(C)=O XUYPXLNMDZIRQH-LURJTMIESA-N 0.000 claims description 4
- UDMBCSSLTHHNCD-KQYNXXCUSA-N adenosine 5'-monophosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O UDMBCSSLTHHNCD-KQYNXXCUSA-N 0.000 claims description 4
- 229950006790 adenosine phosphate Drugs 0.000 claims description 4
- GYOZYWVXFNDGLU-XLPZGREQSA-N dTMP Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)C1 GYOZYWVXFNDGLU-XLPZGREQSA-N 0.000 claims description 4
- 229930182817 methionine Natural products 0.000 claims description 4
- 238000004458 analytical method Methods 0.000 claims description 3
- UDMBCSSLTHHNCD-UHFFFAOYSA-N Coenzym Q(11) Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(O)=O)C(O)C1O UDMBCSSLTHHNCD-UHFFFAOYSA-N 0.000 claims description 2
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims description 2
- 235000003704 aspartic acid Nutrition 0.000 claims description 2
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 claims description 2
- 239000013598 vector Substances 0.000 claims 6
- 230000000975 bioactive effect Effects 0.000 claims 2
- 230000002068 genetic effect Effects 0.000 claims 2
- 239000012264 purified product Substances 0.000 claims 2
- 210000005253 yeast cell Anatomy 0.000 claims 2
- 108090000623 proteins and genes Proteins 0.000 abstract description 14
- 108010007267 Hirudins Proteins 0.000 abstract description 7
- 102000007625 Hirudins Human genes 0.000 abstract description 5
- 238000011144 upstream manufacturing Methods 0.000 abstract description 5
- 238000012216 screening Methods 0.000 abstract description 4
- 239000003146 anticoagulant agent Substances 0.000 abstract 1
- 229940127219 anticoagulant drug Drugs 0.000 abstract 1
- 210000000349 chromosome Anatomy 0.000 abstract 1
- 230000001939 inductive effect Effects 0.000 abstract 1
- 230000002194 synthesizing effect Effects 0.000 abstract 1
- 230000001131 transforming effect Effects 0.000 abstract 1
- 244000286779 Hansenula anomala Species 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 6
- 230000029087 digestion Effects 0.000 description 5
- OTQCKZUSUGYWBD-BRHMIFOHSA-N lepirudin Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O)C(C)C)[C@@H](C)O)[C@@H](C)O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC(C)C)[C@@H](C)O)C1=CC=C(O)C=C1 OTQCKZUSUGYWBD-BRHMIFOHSA-N 0.000 description 5
- 229960004408 lepirudin Drugs 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 241000235648 Pichia Species 0.000 description 4
- 235000001014 amino acid Nutrition 0.000 description 4
- 229940024606 amino acid Drugs 0.000 description 4
- 238000001962 electrophoresis Methods 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 3
- 238000000855 fermentation Methods 0.000 description 3
- 230000004151 fermentation Effects 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 238000004321 preservation Methods 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 108700005078 Synthetic Genes Proteins 0.000 description 2
- 208000007536 Thrombosis Diseases 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000013613 expression plasmid Substances 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 238000007710 freezing Methods 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 108091008146 restriction endonucleases Proteins 0.000 description 2
- 238000010189 synthetic method Methods 0.000 description 2
- 108010042407 Endonucleases Proteins 0.000 description 1
- 102000004533 Endonucleases Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 235000014683 Hansenula anomala Nutrition 0.000 description 1
- 241000235058 Komagataella pastoris Species 0.000 description 1
- 102000003960 Ligases Human genes 0.000 description 1
- 108090000364 Ligases Proteins 0.000 description 1
- 241000500851 Poecilobdella manillensis Species 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000005336 cracking Methods 0.000 description 1
- 230000005611 electricity Effects 0.000 description 1
- 230000001723 fibrinogenic effect Effects 0.000 description 1
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000012807 shake-flask culturing Methods 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
Landscapes
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Description
Claims (14)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB011414154A CN1328380C (zh) | 2001-09-24 | 2001-09-24 | 高效表达水蛭素及其生产方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB011414154A CN1328380C (zh) | 2001-09-24 | 2001-09-24 | 高效表达水蛭素及其生产方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1420176A true CN1420176A (zh) | 2003-05-28 |
CN1328380C CN1328380C (zh) | 2007-07-25 |
Family
ID=4676153
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB011414154A Expired - Fee Related CN1328380C (zh) | 2001-09-24 | 2001-09-24 | 高效表达水蛭素及其生产方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN1328380C (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102373216A (zh) * | 2011-10-28 | 2012-03-14 | 元昊 | 一种含有医用水蛭素基因的重组真核汉逊酵母工程菌株的构建及重组水蛭素的生产工艺 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE4140381A1 (de) * | 1991-12-07 | 1993-06-09 | Hoechst Ag, 6230 Frankfurt, De | Neue synthetische isohirudine mit verbesserter stabilitaet |
CN1088836A (zh) * | 1992-12-30 | 1994-07-06 | 中国科学院生物物理研究所 | 重组水蛭素及其复合物用于制备预防和治疗血栓病药物 |
HUT72926A (en) * | 1993-08-04 | 1996-06-28 | Ciba Geigy Ag | High molecular weight desulphatohirudin |
CN1348003A (zh) * | 2000-10-10 | 2002-05-08 | 梅伯皋 | 水蛭素基因hv2-47k及其合成与表达 |
-
2001
- 2001-09-24 CN CNB011414154A patent/CN1328380C/zh not_active Expired - Fee Related
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102373216A (zh) * | 2011-10-28 | 2012-03-14 | 元昊 | 一种含有医用水蛭素基因的重组真核汉逊酵母工程菌株的构建及重组水蛭素的生产工艺 |
CN102373216B (zh) * | 2011-10-28 | 2013-06-05 | 元昊 | 一种含有医用水蛭素基因的重组真核汉逊酵母工程菌株的构建及重组水蛭素的生产工艺 |
Also Published As
Publication number | Publication date |
---|---|
CN1328380C (zh) | 2007-07-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN112552393B (zh) | 一种重组人源iii型胶原蛋白及其毕赤酵母重组表达系统 | |
CN101501209A (zh) | 具有促胰岛素活性的生物活性多肽的制备方法 | |
CN102439154A (zh) | 一种多核苷酸和多肽链序列及其方法 | |
AU2020392216A1 (en) | Nucleic acids, vectors, host cells and methods for production of beta-fructofuranosidase from Aspergillus niger | |
CN1328380C (zh) | 高效表达水蛭素及其生产方法 | |
CN111094572B (zh) | 一种密码子优化的人胰岛素类似物前体基因和信号肽基因 | |
CN116555320A (zh) | 一种重组人源ⅲ型三螺旋胶原蛋白工程菌及其构建方法和应用 | |
EP2644616A1 (en) | Method for producing web protein, a fused protein, recombinant dna, an expression vector, a host cell and strain-producers | |
CN111320702A (zh) | 一种在甲醇酵母中高效分泌融合表达以及重组制备灵杆菌核酸酶的方法 | |
US20230220358A1 (en) | Nucleic Acids, Vectors, Host Cells and Methods for Production of Fructosyltransferase from Aspergillus Japonicus | |
CN102220345B (zh) | 重组犬α干扰素的优化基因、菌种及高效表达 | |
WO2008139496A1 (en) | Recombinant human insulin and a method thereof | |
CN113249234A (zh) | 一种过表达cat和god的产葡萄糖酸钠的黑曲霉基因工程菌的构建方法 | |
CN1325958A (zh) | 一种生产基因工程重组人溶菌酶的方法 | |
CN1049249C (zh) | 胰岛素前体基因在酵母中的分泌表达和人胰岛素的制备 | |
CN1865430A (zh) | 一种高产促胰岛素激素的毕赤酵母工程菌及其构建方法 | |
CN117050163B (zh) | 一种分泌表达重组iii型胶原蛋白的毕赤酵母工程菌及其应用 | |
RU2306333C2 (ru) | ШТАММ ДРОЖЖЕЙ Pichia pastoris Х-33/2albumin ДЛЯ СЕКРЕЦИИ ЧЕЛОВЕЧЕСКОГО АЛЬБУМИНА | |
CN117701410A (zh) | 介导协氧蛋白和褐藻胶裂解酶的双转录单元重组菌和应用 | |
CN118146354A (zh) | 重组vii型胶原蛋白及其制备方法和应用 | |
CN1326992A (zh) | 一种中国人白细胞介素-18亚型(53A rgIL-18)的基因克隆、产物的制备及应用 | |
AU2003247177A1 (en) | Method for producing target proteins by deleting or amplifying ibpA and/or ibpB gene coding for inclusion body-associated proteins | |
CN1410539A (zh) | 用酵母分泌表达重组人神经生长因子 | |
JPH0638741A (ja) | ヒラメ成長ホルモンの製造法 | |
US20220119494A1 (en) | Recombinant vector, host cell and process for production of human serum albumin |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
ASS | Succession or assignment of patent right |
Free format text: FORMER OWNER: BEIJING LUYIN LIHUA PHARMACEUTICAL TECHNOLOGY DEVELOPMENT CO., LTD. Effective date: 20041029 Owner name: TIANJIN TASLY PHARMACEUTICAL CO., LTD. Free format text: FORMER OWNER: INSTITUTE OF RADIATION MEDICINE, ACADEMY OF MILITARY MEDICAL SCIENCES, PLA |
|
C41 | Transfer of patent application or patent right or utility model | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20041029 Address after: 300402, No. 1, Liaohe East Road, Beichen Science Park, Tianjin Applicant after: Tianjin Tianshili Pharmaceutical Co., Ltd. Address before: 100850 No. 27 Taiping Road, Beijing, Haidian District Applicant before: Institute of Radiation Medicine of Academy of Military Medical Sciences of Chinese People's Liberation Army Co-applicant before: Beijing Luyin Lihua Pharmaceutical Technology Development Co., Ltd. |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
EE01 | Entry into force of recordation of patent licensing contract |
Assignee: Shanghai Tasly Pharmaceutical Co., Ltd. Assignor: Tianjin Tianshili Pharmaceutical Co., Ltd. Contract fulfillment period: 2007.8.1 to 2015.9.24 Contract record no.: 2008120000007 Denomination of invention: High-efficiency expression recombinant hirudin and producing method thereof Granted publication date: 20070725 License type: Exclusive license Record date: 20081029 |
|
LIC | Patent licence contract for exploitation submitted for record |
Free format text: EXCLUSIVE LICENSE; TIME LIMIT OF IMPLEMENTING CONTACT: 2007.8.1 TO 2015.9.24; CHANGE OF CONTRACT Name of requester: SHANGHAI TIANSHILI PHARMACEUTICAL CO., LTD. Effective date: 20081029 |
|
C56 | Change in the name or address of the patentee |
Owner name: TASLY PHARMACEUTICAL GROUP CO., LTD. Free format text: FORMER NAME: TIANJIN TASLY PHARMACEUTICAL CO., LTD. |
|
CP01 | Change in the name or title of a patent holder |
Address after: 300402, No. 1, Liaohe East Road, Beichen Science Park, Tianjin Patentee after: Tasly Pharmaceutical Group Co., Ltd. Address before: 300402, No. 1, Liaohe East Road, Beichen Science Park, Tianjin Patentee before: Tianjin Tianshili Pharmaceutical Co., Ltd. |
|
EC01 | Cancellation of recordation of patent licensing contract |
Assignee: Shanghai Tasly Pharmaceutical Co., Ltd. Assignor: Tasly Pharmaceutical Group Co., Ltd. Contract record no.: 2008120000007 Date of cancellation: 20160826 |
|
EM01 | Change of recordation of patent licensing contract |
Change date: 20160826 Contract record no.: 2008120000007 Assignor after: Tasly Pharmaceutical Group Co., Ltd. Assignor before: Tianjin Tianshili Pharmaceutical Co., Ltd. |
|
LICC | Enforcement, change and cancellation of record of contracts on the licence for exploitation of a patent or utility model | ||
EE01 | Entry into force of recordation of patent licensing contract |
Application publication date: 20030528 Assignee: Shanghai Tasly Pharmaceutical Co., Ltd. Assignor: Tasly Pharmaceutical Group Co., Ltd. Contract record no.: 2016990000365 Denomination of invention: High-efficiency expression recombinant hirudin and producing method thereof Granted publication date: 20070725 License type: Exclusive License Record date: 20160831 |
|
LICC | Enforcement, change and cancellation of record of contracts on the licence for exploitation of a patent or utility model | ||
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20180108 Address after: 201203 Shanghai China (Shanghai) free trade test zone, 280 Curie Road No. 1 and 2 Patentee after: Shanghai Tasly Pharmaceutical Co., Ltd. Address before: 300402, No. 1, Liaohe East Road, Beichen Science Park, Tianjin Patentee before: Tasly Pharmaceutical Group Co., Ltd. |
|
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20070725 Termination date: 20180924 |
|
CF01 | Termination of patent right due to non-payment of annual fee |